Following is the transcript of the Foundation Medicine Inc.’s (NASDAQ:FMI) introduction of the New Interactive Cancer Explorer (ICE) physician portal made on Thursday, January 8, 2015, 10:00 AM ET. The ICE 2, among other updates, features Patient Match, which will enable physicians to connect with other physicians treating patients with similar tumor profiles.
Foundation Medicine, Inc. (NASDAQ:FMI) is a molecular information company. It offers tests that help oncologists choose treatments for their patient’s unique cancers by providing fully informative genomic profiles that can be matched with targeted therapies and clinical trials. The company’s molecular information platform is targeted towards improving day-to-day care for cancer patients as well as aims to advance molecular medicine in cancer diagnosis and treatments.
Company Representatives
Steven Kafka, Chief Operating Officer, Foundation Medicine, Inc.
Gaurav Singal, Director of Innovations, Foundation Medicine, Inc.
Operator
Good day, ladies and gentlemen, and welcome to the Introducing Foundation Medicine’s New Interactive Cancer Explorer. At this time, all participants are on a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instruction). As a reminder, this conference call is being recorded. I would now like to introduce your host for today’s conference,Foundation Medicine Incorporated. Please go ahead.
Steven Kafka, Chief Operating Officer, Foundation Medicine, Inc.
Good morning and thank you for joining us this morning for our webinar, Introducing the New Version of our Interactive Cancer Explorer, ICE 2. I’m Steve Kafka, Chief Operating Officer of Foundation Medicine. Joining me this morning is Dr. Gaurav Singal, Director of our Innovations unit, who together with the terrific team here at Foundation Medicine, has designed and built ICE 2. Gaurav is a physician and computer scientist who joined us from the Massachusetts General Hospital, where he completed his residency and also led the development of a physician-facing EMR application that uses natural language processing to automate chart review.
Today, we are excited to introduce you to ICE2,which was launched last month and is our next generation platform created to enable physicians to increase the efficiency of patient care and enhance the utility of our tests.
This new platform allows physicians in a HIPAA-complaint fashion to access results from our comprehensive genomic profiling tests to obtain information about potential treatment options and clinical trials and to connect with other physicians who have treated similar patients to share treatment and outcomes data. Among other updates, we were particularly excited about a key new feature of ICE2, PatientMatch. PatientMatch is a tool that leverages the now more than 27,000 patient cases in our knowledge base to enable physicians who are facing an increasingly complex cancer landscape to interact with one another regarding treatment options for patients with similar tumor and genomic profiles.
We believe the combination of these features is important in integrating ICE2 into the daily workflow of physicians. No other network connects physicians in this way. In many ways, we are building on what physicians do each and every day, namely, relying on their colleagues to discuss challenging treatment scenarios. But now, we have been enabled physicians to take this practice to scale. This ability to exchange information in real time and learn from one another must be an essential component of this transformation in cancer care, which is rapidly moving towards a precision-based approach.
Adaption of our comprehensive genomic profiling products within the clinical setting continues to grow, and the introduction of ICE 2 is an exciting step toward ultimately enabling more informed treatment options for patients.
I now turn things over to Gaurav to introduce you to the concept and key features of ICE 2, after which, we will open the lines up for your questions. Gaurav?
